

**Customer Number** 

Docket No.:58232US004

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KEITH B. GORDEN, XIAOHONG QUI and JOHN P. VASILAKOS

Serial No.:

10/777,310

Filed:

February 12, 2004

For:

**METHODS AND** 

COMPOSITIONS RELATED TO

IRM COMPOUNDS AND TOLL-

LIKE RECEPTOR 8

Group Art Unit:

1615

Examiner:

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. Copies of any cited foreign patents, non-patent literature, and unpublished US application documents are enclosed. Pursuant to the waiver in the Pre-OG Notice, dated July 25, 2003, copies of US patents and published US patent applications are no longer required and are not enclosed. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Should a First Office Action on the merits be mailed prior to the filing of this Disclosure Statement, please charge the requisite \$180.00 fee (pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p)) to Deposit Account No. 13-3723.

08/17/2004 EAREGAY1 00000015 133723 10777310

01 FC:1806

180.00 DA

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS. P.O. BOX 1450 ALEXANDRIA, VA 22313-1450 ON

Applicants submit that the above references, whether taken alone or in combination with each other neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to the captioned application is respectfully requested.

Respectfully submitted,

CHRISTOPHER D. GRAM Registration No. 43,643 Attorney for Applicants

CDG:jlh/58232US004IDS Office of Intellectual Property Counsel 3M Innovative Properties Company P.O. Box 33427 St. Paul, Minnesota 55133-3427 (651) 733-1507 Facsimile: (651) 736-3833

Dated: August 12, 2004

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) AU6 1 6 2004

Page 1 of 5

10/777,310
February 12, 2004
Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
1615
Unknown
58232US004

			U.S. Patent	Documents	Pages, Columns, Lines, Where
xam.	Cite No.	Document Number  Doc. Number-(Kind Code if Known)	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	<b> </b> +	US- 4,689,338	08-25-1987	Gerster	
	<b>↓</b>	US- 4,698,348	10-06-1987	Gerster	
	<del>                                     </del>	US- 4,929,624	05-29-1990	Gerster et al.	
	A3 A4	US- 4,988,815	01-29-1991	Andre et al.	
	A5	US- 5,037,986	08-06-1991	Gerster	
	A6	US- 5,175,296	12-29-1992	Gerster	
	A7	US- 5,238,944	08-24-1993	Wick et al.	
	A8	US- 5,266,575	11-30-1993	Gerster et al.	
	A9	US- 5,268,376	12-07-1993	Gerster	
	A10	US- 5,346,905	09-13-1994	Gerster	
	A11	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A12	US- 5,367,076	11-22-1994	Gerster	
	A13	US- 5,376,501	12-27-1994	Mariën et al.	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A17	US- 5,482,936	01-09-1996	Lindstrom	
	A18	US- 5,494,916	02-27-1996	Lindstrom et al.	
	A19	US- 5,525,612	06-11-1996	Gerster	
	A20	US- 5,605,899	02-25-1997	Gerster et al.	
<del>                                     </del>	A21		12-02-1997	Lindstrom	
	A22		04-21-1998	Gerster et al.	
	A23		05-26-1998	Gerster	
	A24		08-17-1999	Beaurline et al.	
	A25		02-22-2000		
	A26		03-21-2000		
-	A27	7 US- 6,069,149	05-30-2000		
	A28	3 US- 6,083,505	07-04-2000		
	A29	9 US- 6,110,929	08-29-2000	Gerster et al.	

*Examiner:	Date Considered:
Examiner.	is in conformance with MPEP 609. Draw line through citation if not in

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 2 of 5

Application Number	10/777,310
Filing Date	February 12, 2004
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
Art Unit	1615
Examiner Name	Unknown
Attorney Case Number	58232US004

			U.S. Patent	Documents	Pages, Columns, Lines, Where
Exam.	Cite No.	Document Number  Doc. Number-(Kind Code if Known)	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
———	<b>↓</b> +	US- 6,113,918	09-05-2000	Johnson et al.	
		US- 6,194,388 B1	02-27-2001	Krieg et al.	
	1	US- 6,194,425 B1	02-27-2001	Gerster et al.	
	A33	US- 6,200,592 B1	03-13-2001	Tomai et al.	
	A34	US- 6,207,646 B1	03-27-2001	Krieg et al.	
	A35	US- 6,239,116 B1	05-29-2001	Krieg et al.	
	A36	US- 6,245,776 B1	06-12-2001	Skwierczynski et al.	
	A37	US- 6,303,347 B1	10-16-2001	Johnson et al.	
	A38	US- 6,323,200 B1	11-27-2001	Gerster et al.	
	A39	US- 6,329,381 B1	12-11-2001	Kurimoto et al.	
	A40	US- 6,331,539 B1	12-18-2001	Crooks et al.	
	A41	US- 6,339,068 B1	01-15-2002	Krieg et al.	
	A42	US- 6,376,501 B1	04-23-2002	Isobe et al.	
	A43	US- 6,376,669 B1	04-23-2002	Rice et al.	
<del>                                     </del>	A44	US- 6,387,938 B1	05-14-2002	Mizuguchi et al.	
	A45	US- 6,406,705 B1	06-18-2002	Davis et al.	
<u> </u>	A46	US- 6,426,334 B1	07-30-2002	Agrawal et al.	
	A47	US- 6,440,992 B1	08-27-2002	Gerster et al.	
-	A48	US- 6,476,000 B1	11-05-2002	Agrawal	
	A49	US- 6,451,810 B1	09-17-2002	Coleman et al.	
	A50	US- 6,514,985 B1	02-04-2003	Gerster et al.	
	A51	US- 6,518,265 B1	02-11-2003	Kato et al.	
	A52	US- 6,518,280 B2	02-11-2003	Gerster et al.	
	A53	US- 6,525,028 B1	02-25-2003	Johnson et al.	
	A54	US- 6,525,064 B1	02-25-2003	Dellaria et al.	
	A55	US- 6,541,485 B1	04-01-2003		
	A56	US- 6,545,016 B1	04-08-2003		
	A57	US- 6,545,017 B1	04-08-2003		
	A58	US- 6,558,951 B1	05-06-2003	Tomai et al.	

*Examiner:	Date Considered:
Examiner.	is in conformance with MPEP 609. Draw line through citation if not in

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 3 of 5

Application Number	10/777,310
Filing Date	February 12, 2004
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
Art Unit	1615
Examiner Name	Unknown
Attorney Case Number	58232US004

			U.S. Patent		Pages, Columns, Lines, Where
Exam.	Cite	Document Number	Publication Date or Issue Date	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
Init.*	No.	Doc. Number-(Kind Code if Known)	MM-DD-YYYY	Crooks et al.	
	A59	US- 6,573,273 B1	06-03-2003		
	A60	US- 6,649,172 B2	11-18-2003	Johnson	
	A61	US- 6,656,938 B2	12-02-2003	Crooks et al.	
	A62	US- 6,660,735 B2	12-09-2003	Crooks et al.	
	A63	US- 6,660,747 B2	12-09-2003	Crooks et al.	
	A64	US- 6,664,260 B2	12-16-2003	Charles et al.	
	A65	US- 6,664,264 B2	12-16-2003	Dellaria et al.	
	A66	US- 6,664,265 B2	12-16-2003	Crooks et al.	
	A67	US- 6,667,312 B2	12-23-2003	Bonk et al.	
	A68	US- 6,670,372 B2	12-30-2003	Charles et al.	
	A69	US- 6,677,347 B2	01-13-2004	Crooks et al.	
	A70	US- 6,677,348 B2	01-13-2004	Heppner et al.	
	A71	US- 6,677,349 B1	01-13-2004	Griesgraber	
}	A72	US- 6,683,088 B2	01-27-2004	Crooks et al.	
<u> </u>	A73	US- 2002/0016332 A1	02-07-2002	Slade	
-	A74		05-09-2002	Smith	
-	A75	777777777777777777777777777777777777777	05-16-2002	Hedenstrom et al.	
-			08-15-2002	Tomai et al.	
-	A76		07-17-2003	Tomai et al.	
-	A77	1000004 44	07-24-2003		
-	A78		07-31-2003	1 -1	
-	A79		10-23-2003	Averett et al.	
-	A80		01-22-04	Gorden et al.	
_	A8		01-15-2004	Dellaria et al.	
-	A8:	2 US- 2004/0010007 A1			

1	A8Z	03- 200-	70010001711				
			Fo	reign Patent	Documents		
Exam.	Cite	Fore	eign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MIVI-DD-1111		Of Notional State of the State	×
	B1	EP	0 394 026	10-24-1990			X
	B2	EP	1 104 764 A1 /	06-06-2001			

	_
*Exam	inor.
Exall	111161.

**Date Considered:** 

Exam.

Init.\*

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 4 of 5

10/777,310
February 12, 2004
Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
1615
Unknown
58232US004

	Cito	Fore	eign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Translation (Check if yes)
xam. Init.*	Cite No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	
	B3	JР	9-208584	08-12-1997			+ x
	B4	JP	11-80156	03-26-1999	(translation only)		X
	B5	JP	11-222432	08-17-1999			X
	B6	JP	2000-247884 (abstract only)	09-12-2000			X
	B7	wo	00/47719 A2	08-17-2000			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	B8	wo	00/75304 A1	12-14-2000			
<u> </u>	B9	wo	00/76505 A1	12-21-2000		<u> </u>	
	B10	wo	00/76518A1	12-21-2000			+ ^
	B11	wo	01/74343 A2	10-11-2001			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	B12	wo	02/36592 A1	05-10-2002			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	B13	wo	02/46188 A2	06-13-2002			- X
	B14	wo	02/46189 A2	06-13-2002			$\frac{1}{x}$
	B15	+	02/46190 A2	06-13-2002			1 ^ x
	B16	wo	02/46191 A2	06-13-2002	:	<del></del>	
	B17	wo	02/46192 A2	06-13-2002			$\frac{\hat{x}}{x}$
	B18		02/46193 A2	06-13-2002	2		- ^ ×
-	B19	<del></del>	02/46194 A2	06-13-2002			
-	B20	) wo	02/46749 A2	06-13-2002			
	B21		02/085905 A1	10-31-2002			x
<u> </u>	B22	2 WO	02/102377 A1	12-27-2002	2		$\frac{\lambda}{x}$
	B23	3 WO	03/020889 A2	03-13-200	-	·	$\frac{}{x}$
-	B24	4 WO	03/043572 A2	05-30-200			$\frac{}{x}$
-	B2	5 WO	03/045391 A1	06-05-200			$^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^$
-	B2	6 WO	03/103584 A2	12-18-200	13		

	C1	Testerman, et al., "Cytokine Induction by of Leukocyte Biology, Volume 58, pp. 36	55-372, September 1995.	
*Examiner:			Date Considered:	
	MINER: Initial if reference considered, whether or not citation or manager and not considered. Include copy of this form with		is in conformance with MPEP 609. Draw line through citation if not in ext communication to applicant.  PTO-1449 (Modified)	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 5 of 5

the state of the s	to the same to	
Application Number	10/777,310	
Filing Date	February 12, 2004	
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos 1615	
Art Unit		
Examiner Name	Unknown	
Attorney Case Number	58232US004	

		Authora Title Date Pertinent Papers, etc.)					
	OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)						
Exam.	Cite No.	lnclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, points, some, some property catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
iiii.	C2	C2 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C2 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C2 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C3 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C3 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C4 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C5 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C5 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C5 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C5 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C5 Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical C5 Chollet, et al, "Development of a Topical C5 Chollet, et al, "Development of a Topical C5 C6					
	C3	Brassard et al.; "Interferon-α as an immunotherapeutic protein"; Journal of Leukocyte Biology, vol.					
	C4	Izumi et al.; "1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinoline Derivatives as Novel Potent TNF-d Supplessors. Synthesis and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolines or 1 <i>H</i> -and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -and 3-and					
•	C5	Hornung et al., "Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Celular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", The Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxynucleoxy					
	C6	Hemmi et al., "Small anti-viral compounds activate immune cells via the TER7 MyD00-dependent learning and the restrict myd00-dependent learning and the rest					
/	C7	Medzhitov, "Toll-Like Receptors and Innate Immunity", Nature Reviews Immunicagy, Vol. 1,					
	C8	Jurk et al. "Human TLR7 and TLR8 independently confer responsiveness to the antivital compound of the second secon					
	C9	Akira et al., "Toll-like receptors: critical proteins linking innate and acquired infindinty, vectors					
	C10	Heil et al.; "Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8"; 33th Annual Meeting of the Deutsche Gessellschaft für Immunologie, Marburg 2002 - Abstract C.6					

*Eva	mi	no	۳.
~FYA	mı	ne	1

**Date Considered:**